Research and Development Expense (TTM) Chart

Historical Research and Development Expense (TTM) Data

View and export this data back to 2019. Start Trial.
Date Value
September 30, 2026 30.76M
June 30, 2026 32.99M
March 31, 2026 34.08M
December 31, 2025 35.38M
September 30, 2025 28.61M
June 30, 2025 25.44M
March 31, 2025 23.03M
December 31, 2024 18.39M
September 30, 2024 16.00M
June 30, 2024 12.51M
March 31, 2024 9.72M
December 31, 2023 9.448M
September 30, 2023 8.782M
June 30, 2023 9.802M
March 31, 2023 15.65M
Date Value
December 31, 2022 24.29M
September 30, 2022 36.73M
June 30, 2022 48.32M
March 31, 2022 55.84M
December 31, 2021 60.79M
September 30, 2021 61.44M
June 30, 2021 64.38M
March 31, 2021 63.75M
December 31, 2020 61.31M
September 30, 2020 55.48M
June 30, 2020 46.75M
March 31, 2020 39.77M
December 31, 2019 30.21M
September 30, 2019 22.47M
June 30, 2019 16.63M

R&D Expense Definition

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (TTM) Range, Past 5 Years

View Research and Development Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (TTM) Benchmarks

View Research and Development Expense (TTM) Benchmarks
Start Trial
Korsana Biosciences, Inc. 43.39M
PepGen Inc. 52.70M
Q32 Bio, Inc. 15.94M
Bridgebio Oncology Therapeutics, Inc. 156.69M
Oncolytics Biotech, Inc. 13.18M